Candidiasis Therapeutics Market Size

Candidiasis Therapeutics Market Analysis

The candidiasis therapeutics market is expected to register a CAGR of 5.1% over the forecast period.

The COVID-19 pandemic impacted the market studied significantly in the initial phase. Due to the lockdown and shutdowns, global trade was affected drastically, and the supply chain of pharmaceuticals was disrupted, which hampered the sales of candidiasis drugs and therapeutics. However, even though the market initially showed a decline in sales, the increasing number of infections during the pandemic phase increased the demand for candidiasis therapies. Fungal co-infections were found along with COVID-19 infections. For instance, according to an article published by PubMed Central in March 2022, COVID-19-associated candidiasis was widely recognized as a part of severe COVID-19 consequences during the pandemic. The article also stated that factors responsible for the co-infection were a compromised immune system, iron and zinc deficiencies, and nosocomial and iatrogenic transmissions. Thus, the demand for innovative therapies increased for candidiasis infection during the pandemic. However, in the post-pandemic period, the market studied is expected to have stable growth during the forecast period.

Furthermore, the growing prevalence of candidiasis infection is further driving the demand for new therapeutics for treatment, augmenting the market's growth. The global burden of candida infection is currently rising. For instance, among all the other countries globally, Zimbabwe is one of the major countries affected by several healthcare challenges. According to an article by Nature in June 2021, the estimated prevalence of recurrent vulvovaginal candidiasis (RVVC) was 2,739/100,000 in Zimbabwe, and the estimated burden is high compared to other African countries. These prevalent cases of candidiasis in low-income countries like Zimbabwe and others are creating demand for the availability of better and more advanced therapeutics, which in turn is expected to impact the growth of the market studied.

Moreover, candidiasis in the mouth or oral candidiasis is one of the most common infections affecting most of the population globally. The persistent oral infection among the population requires treatment to combat the spread of the infection, further boosting the growth of the market studied. An article updated in the National Library of Medicine in March 2022 reported that oral candidiasis can occur in immunocompetent or immunocompromised patients. But this is more common in immunocompromised hosts. This oral candidiasis occurs equally in males and females, typically in neonates and infants. The global burden of candidiasis is growing with the rising population globally. Hence, the therapeutics for candidiasis have become more critical. Therefore, the burden of oral candidiasis is expected to drive the market for candidiasis therapeutics in the future.

In addition, the growing awareness of candidiasis infection among the target population and product innovation in all market segments are driving the demand for new therapeutics. For instance, in September 2021, Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, presented new clinical and non-clinical data for its Rezafungin in two poster presentations at the 10th Congress on Trends in Medical Mycology (TIMM) Webinar which took place in Aberdeen, Scotland. Rezafungin is a novel once-weekly echinocandin which is being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. Hence, product innovation is expected to boost the market growth.

Therefore, the studied market is predicted to see growth over the forecast period owing to the aforementioned factors. However, narrow pipeline molecules and competition from herbal medicines and alternative therapies can hinder the market growth.